Celcuity Inc. announced on September 9, 2025, an amendment to its existing senior secured credit facility, significantly increasing its total term loan facility size to $500 million. This includes $350 million in committed capital and up to an additional $150 million at the mutual discretion of Celcuity and its lenders.
At the closing of this amendment, an initial funding of $30 million was made, bringing the total term loan outstanding to $130 million. This upsized facility follows the positive topline data from the PIK3CA wild-type cohort of the pivotal VIKTORIA-1 Phase 3 clinical study.
The enhanced financial flexibility and access to capital will support the rolling submission of Celcuity's New Drug Application (NDA) to the FDA via the Real-Time Oncology Review (RTOR) program. It will also fund commercial launch preparations for gedatolisib and other strategic initiatives, extending the company's operational runway.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.